Sézary Syndrome: A Crucial Cause of Uncontrollable Itching

Authors

  • Diana Isabel Rocha Serviço de Medicina Interna, Unidade Local de Saúde Santo António, Porto, Portugal
  • Ana Novo Serviço de Medicina Interna, Unidade Local de Saúde Santo António, Porto, Portugal
  • Sofia Moura Azevedo Serviço de Medicina Interna, Unidade Local de Saúde Santo António, Porto, Portugal
  • Daniela Barroso Serviço de Medicina Interna, Unidade Local de Saúde Santo António, Porto, Portugal

##plugins.pubIds.doi.readerDisplayName##:

https://doi.org/10.60591/crspmi.181

Keywords:

Lymphoma, T-Cell, Cutaneous; Mycosis Fungoides, Pruritus/etiology, Sezary Syndrome/complications

Abstract

Erythroderma is a challenging condition characterized by
widespread erythema involving over 80% of the body surface, often with an unknown cause. Determining the etiology of erythroderma is a complex task due to its association with various pathologies. Sézary syndrome (SS), an aggressive leukemic variant of cutaneous T-cell lymphoma (CTCL), is one of the potential causes, leading to a traditionally poor short-term prognosis. Swift diagnosis is crucial as it significantly impacts the morbidity and mortality of these patients.

We present a clinical case of erythroderma associated with
SS, emphasizing the importance of early recognition and diagnosis of erythroderma associated with CTCL, since it has a significant impact on the morbidity and mortality of these patients.

References

Hojouj IM, Bondarenko VZ, Maltseva L, Elhaj M. A rare case of sezary syndrome cutaneous T-cell lymphoma with complete response. J Biotech Biores.2019;2:1-2. doi: JBB.000531.2019

Miyashiro D, Sanches JA. Mycosis fungoides and Sézary syndrome: clinical presentation, diagnosis, staging, and therapeutic management. Front Oncol. 2023;13:1141108. doi: 10.3389/fonc.2023.1141108.

Fuentes GL, Rodríguez RZ, Rodríguez PA. Erythroderma and cutanous T-cell lymphomas. Mul Med. 2020;24:1197-209.

Reifs CM, Salido-Vallejo R, Garnacho-Saucedo GM, Corte-Sánchez S, González-Menchen A, García-Nieto AV. Alemtuzumab in refractory

Sézary syndrome. An Bras Dermatol. 2016;91:642-4. doi: 10.1590/ abd1806-4841.20164322.

Brigham BA, Bunn PA Jr, Horton JE, Schechter GP, Wahl LM, Bradley EC, et al. Skeletal manifestations in cutaneous T-cell lymphomas. Arch Dermatol. 1982;118:461-7.

Spicknall KE. Sézary syndrome-clinical and histopathologic features, differential diagnosis, and treatment. Semin Cutan Med Surg. 2018 Mar;37(1):18-23. doi: 10.12788/j.sder.2018.005.

Fernandes NC, Pereira FS, Maceira JP, Cuzzi T, Dresch TF, Araújo PP. Eritrodermia: estudo clínico-laboratorial e histopatológico de 170

casos. An Bras Dermatol. 2008;83:526–32. doi: 10.1590/S0365-05962008000600005

Cariti C, Quaglino P, Lupia T, Novelli M, Marra E, Fava P, et al. Infections in Sézary syndrome: A retrospective cohort study of 113

patients. J Am Acad Dermatol. 2022;86:943-46. doi: 10.1016/j. jaad.2021.03.079.

Published

2024-06-24

How to Cite

Rocha, D. I., Novo, A., Moura Azevedo, S., & Barroso, D. (2024). Sézary Syndrome: A Crucial Cause of Uncontrollable Itching. SPMI Case Reports, 2(Edição Especial), 58–61. https://doi.org/10.60591/crspmi.181

Most read articles by the same author(s)